Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Lithium for bipolar disorder preserves neurocognitive functioning

28 Aug 2020

In the treatment of patients with bipolar disorder, lithium gets the job done without significantly impairing cognition, as shown in a study.

The analysis included 262 patients (mean age, 42.7 years; 45.9 percent) with bipolar disorder, among whom 169 were taking lithium. Compared with users, nonusers of lithium were younger (p=0.002), less likely to be white (p<0.001), and had more severe current manic and depressive symptoms (both self-reported and clinician-assessed; p<0.001).

At baseline, users and nonusers performed similarly on the following neurocognitive tests: California Verbal Learning Test (CVLT) trials 1–5, CVLT delayed recall, Wechsler Digit Symbol, Trail-making Test (TMT) parts A and B, and global cognition index. This was despite controlling for demographics and current mood symptoms.

At follow-up, however, lithium users exhibited a significant neurocognitive improvement in the global cognitive index score (p<0.001), CVLT trials 1–5 (p<0.001), CVLT delayed recall (p<0.001), and TMT-B (p=0.012). The average duration between the first and the second neurocognitive assessment was 132.1 days. None of the cognitive measures declined over time with treatment.

Overall, the data indicate that lithium exerts no deleterious effects on neurocognitive functioning, despite the frequent subjective complaints of cognitive dulling by users. Researchers speculated that these subjective self-reports after lithium initiation may be related more directly to stabilization of affective symptoms that may be deemed as positive (eg, hypomania) for the patient.

The researchers suggested that clinicians discuss with their patients the pros and cons of lithium in mood stabilization.

Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.